微信内可能无法直接打开本站。请点右上角 ··· → 在浏览器打开，或复制链接。
STAT+: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
RSS 官方收录 · 可信分层展示
关键摘要
阿斯利康心衰药III期试验失败：已用稳定剂患者加用沉默剂无额外获益
- ATTR-CM患者联用沉默剂与稳定剂未见额外疗效
- 超半数受试者基线已服用稳定剂致试验失败
- 结果强化口服稳定剂优于注射沉默剂的市场认知
AI 摘要 · 来源可核验
正文提要
AstraZeneca on Friday detailed the surprise failure of a closely watched heart disease clinical trial, laying out how its experimental drug offered no additional benefits for patients who were largely already on another type of medicine — the latest twist in a multi-billion dollar market.
The study indicated that patients with a progressive condition known as ATTR-CM who received AstraZeneca’s drug — what’s called a silencer — saw no improvements if they were already taking another type of drug called a stabilizer, an effect so powerful that it tanked the whole Phase 3 study. Most participants were on a stabilizer at the outset of the trial.
The trial’s miss has had implications not just for AstraZeneca and its development partner Ionis Pharmaceuticals, but for other companies that market ATTR-CM drugs, including Alnylam Pharmaceuticals, which sells another silencer, and BridgeBio, the maker of a new stabilizer. Analysts have said the study’s outcome bolstered the case that stabilizers, which are oral drugs, were perhaps superior to injectable silencers.